Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors

Tools
- Tools
+ Tools

Smith, M. J., Smith, H. G., Mahar, A. L., Law, C., Ko, Y. J. (2016) The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors. International Journal of Cancer, 139 (8). pp. 1744-1751. ISSN 0020-7136

Full text not available from this repository.

Abstract

A higher incidence of additional malignancies has been described in patients diagnosed with gastrointestinal stromal tumors (GIST). This study aimed to identify risk factors for developing additional malignancies in patients diagnosed with GIST and evaluate the impact on survival. Individuals diagnosed with GIST from 2001 to 2009 were identified from the SEER database. Logistic regression was used to identify predictors of additional malignancies and Cox-proportional hazards regression used to identify predictors of survival. In the study period, 1705 cases of GIST were identified, with 181 (10.6%) patients developing additional malignancies. Colorectal cancer was the most common cancer developing within 6 months of GIST diagnosis (30%). The median time to diagnosis of a malignancy after 6 months of GIST diagnosis was 21.9 months. Older age (p < 0.0001) and extraoesophagogastric GIST (p=0.0027) were significant prognostic factors associated with additional malignancies. The overall 5-year survival was 65%, with the presence of additional malignancies within 6 months of GIST diagnosis associated with poor overall survival (54%, HR 1.55 1.05-2.3 95% CI, p=0.04). Predictive factors of additional malignancies in patients diagnosed with GIST are increasing age and the primary disease site. Developing additional malignancies within 6 months of GIST diagnosis is associated with poorer overall survival. Targeted surveillance may be warranted in patients diagnosed with GIST that are at high risk of developing additional malignancies.

Item Type: Article
All Authors: Smith, M. J., Smith, H. G., Mahar, A. L., Law, C., Ko, Y. J.
Additional Information: ISI Document Delivery No.: DV9TH Times Cited: 0 Cited Reference Count: 32 Smith, Myles J. Smith, Henry G. Mahar, Alyson L. Law, Calvin Ko, Yoo-Joung Hanna Family Research Chair in Surgical Oncology Dr Calvin Law is supported by the Hanna Family Research Chair in Surgical Oncology. 0 WILEY-BLACKWELL HOBOKEN INT J CANCER
Uncontrolled Keywords: gastrointestinal stromal tumors second cancers gist sarcoma second primary care seer colorectal care survival RENAL-CELL CARCINOMA ADJUVANT IMATINIB GIST TRIAL EPIDEMIOLOGY SURVEILLANCE EXPRESSION CAUSATION NEOPLASMS OUTCOMES
Research teams: Clinical Units > Academic Surgery
Depositing User: Barry Jenkins
Date Deposited: 14 Oct 2016 14:58
Last Modified: 14 Oct 2016 14:58
URI: http://publications.icr.ac.uk/id/eprint/15356

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust